Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting
Magenta Therapeutics (NASDAQ: MGTA) announced data presentations at the EBMT 2021 annual meeting, emphasizing advancements in stem cell mobilization and conditioning therapies. Significant findings include the oral presentation of MGTA-145, which showed effective mobilization of hematopoietic stem cells combined with plerixafor, and the poster presentation of MGTA-117, a targeted conditioning agent for stem cell transplants. MGTA-117 is anticipated to enter clinical trials in mid-2021, addressing a critical need for safer conditioning regimens in treating acute myeloid leukemia and myelodysplastic syndromes.
- Successful oral presentation of MGTA-145 demonstrating effective stem cell mobilization.
- MGTA-117 showed potent efficacy in preclinical models, supporting upcoming IND filing.
- MGTA-145 and plerixafor offer a promising one-day mobilization regimen with potential to improve patient outcomes.
- Clinical trials and regulatory approvals for MGTA-117 are still pending, introducing uncertainty.
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced availability of data presentations across its stem cell mobilization and targeted conditioning programs at the European Society for Blood and Marrow Transplantation (EBMT) 2021 annual meeting, held virtually March 14-17, 2021.
“The EBMT Annual Meeting is one of the most important gatherings of global scientific and medical experts in the field of stem cell transplantation and cellular therapy and a key opportunity for Magenta to highlight our findings in our mobilization and conditioning programs,” said John Davis Jr., M.D., M.P.H., M.S., Magenta’s Head of Research & Development and Chief Medical Officer. “We are encouraged and excited by the advances we are making at Magenta and across the entire field, and what that means for the patients we seek to serve.”
Oral Presentation of Final Phase 1 MGTA-145 Stem Cell Mobilization Program
Magenta is developing MGTA-145 plus plerixafor to harness these agents’ complementary mechanisms to mobilize hematopoietic stem cells (HSCs) for collection and transplantation, including for use with gene therapies. The ability to provide rapid, reliable, predictable and safe mobilization and collection of HSCs in stem cell transplantation could position MGTA-145 plus plerixafor to be the preferred mobilization regimen across multiple diseases due to improved patient experience and collection outcomes.
Title: MGTA-145, In Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties (Oral Presentation, OS1-1)
Presenting Author: Kevin Goncalves, Ph.D., Magenta Therapeutics
To view: OS1 Oral Session 1: Hematopoietic Stem Cells, Mobilization and Engineering; held Sunday, March 14, and currently available on-demand via the conference’s website
Data from this Phase 1 clinical trial with healthy volunteers further underscore the potential utility of MGTA-145 plus plerixafor as an effective, single-day mobilization and collection regimen for autologous and allogeneic HSC transplant. MGTA-145 plus plerixafor rapidly mobilized large numbers of HSCs and showed durable engraftment, successful gene-modification and immunosuppressive properties by reducing Graft-versus-Host disease (GvHD) in preclinical models. This abstract is an encore presentation by the Company.
This abstract was selected as one of 10 of the conference’s “Best Young Abstracts,” honoring top-scored abstracts submitted by those under 35 years of age. The awards will be presented during the Poster Session, Tuesday, March 16 at 6:00pm CET.
Poster Presentation of a Preclinical Study of MGTA-117 Targeted ADC Conditioning Program
Magenta is developing a platform of novel antibody-drug conjugates (ADCs) for conditioning, a step in the transplant process that currently relies on the use of systemic chemotherapy agents and radiation. Magenta’s targeted conditioning programs are designed to selectively eliminate stem cells and/or immune cells from a patient prior to stem cell transplant or gene therapy. The conditioning ADCs have the potential to reduce or eliminate the need for high dose or high intensity chemotherapy-based conditioning regimens.
MGTA-117, Magenta’s most advanced conditioning program, is a CD117-targeted antibody conjugated to amanitin and intended for use in patients undergoing transplant or gene therapy. MGTA-117 is designed to deplete hematopoietic stem cells and clear space in the bone marrow prior to transplant to enable long-term engraftment and improved disease outcomes in patients. MGTA-117 has shown high selectivity, potent efficacy and tolerability in multiple preclinical studies.
The Company expects to file an Investigational New Drug (IND) application for MGTA-117 in mid-2021, and, upon acceptance of the IND by the U.S. FDA, Magenta plans to initiate a Phase 1/2 clinical trial to evaluate MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with initial safety and pharmacokinetic data available for internal assessment by Q4 2021. These initial data are expected to be directional for the Company’s dose escalation plans.
Title: A Novel Short Half-life Anti-Human CD117-Amanitin ADC Exhibits Dual HSCT Conditioning and Anti-Leukemia Activity and Extends Survival in Multiple Preclinical Models of AML (Abstract #P197)
Author: Leanne Lanieri, M.S., Magenta Therapeutics
To view: Available in the ePoster area of the virtual event
Hematopoietic stem cell transplant (HSCT) can often be a curative treatment for patients with AML. There is currently a need for safer and more effective targeted conditioning agents, as current conditioning regimens are associated with severe toxicities and high post-transplant relapse or graft failure. MGTA-117 was studied in multiple human leukemic xenograft murine models to mimic untreated and refractory AML. In preclinical models, MGTA-117 significantly increased median survival versus a multi-day treatment of cytarabine, the clinical comparator. This abstract is an encore presentation by the Company.
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.
Follow Magenta on Twitter: @magentatx.
Forward-Looking Statement
This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Magenta’s future expectations, plans and prospects, including, without limitation, statements regarding expectations and plans for presenting clinical data, projections regarding our long-term growth, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates and advancement of our clinical programs, as well as other statements containing words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions that can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from pre-clinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials or to market products; whether Magenta's cash resources will be sufficient to fund Magenta's foreseeable and unforeseeable operating expenses and capital expenditure requirements; risks, assumptions and uncertainties regarding the impact of the continuing COVID-19 pandemic on Magenta’s business, operations, strategy, goals and anticipated timelines, Magenta’s ongoing and planned pre-clinical activities, Magenta’s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, Magenta’s timelines for regulatory submissions and Magenta’s financial position; and other risks concerning Magenta's programs and operations set forth under the caption “Risk Factors” in Magenta’s Annual Report on Form 10-K filed on March 3, 2021, as updated by Magenta’s most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005201/en/
FAQ
What is the purpose of MGTA-145?
When will MGTA-117 enter clinical trials?
What are the results of the MGTA-145 study?
What are the implications of the MGTA-117 program?
How does the EBMT 2021 presentation affect Magenta's stock?
